Monstad S E, Drivsholm L, Storstein A, Aarseth J H, Haugen M, Lang B, Vincent A, Vedeler C A
Department of Neurology, 200301028, Haukeland University Hospital, Jonas Liesvei 65, Bergen 5021, Norway.
J Clin Oncol. 2004 Mar 1;22(5):795-800. doi: 10.1200/JCO.2004.01.028.
Hu antibodies previously have been associated with longer survival of patients with small-cell lung cancer (SCLC). Voltage-gated calcium channel (VGCC) antibodies play a pathogenic role in Lambert Eaton myasthenic syndrome, which is also associated with SCLC. These antibodies may reduce tumor growth in patients with the neurologic disease, but it is not clear whether they provide prognostic information in those without neurologic symptoms.
Two hundred patients with SCLC (age 39 to 79 years; mean, 62.3 years; 129 males and 71 females) receiving chemotherapy were studied for the presence of Hu and VGCC antibodies. Sera were examined for Hu antibodies by an in vitro transcription-translation-based immunoprecipitation technique and by immunohistochemistry/dot blot. VGCC (P/Q subtype) antibodies were detected by radioimmunoassay. Survival analysis was used to analyze the data. Results Hu antibodies were detected in 51 of 200 patients (25.5%) by in vitro transcription-translation-based immunoprecipitation and in 37 of 200 patients (18.5%) by immunohistochemistry or dot blot, whereas VGCC antibodies were detected in only 10 of 200 patients (5%). The presence of Hu antibodies did not correlate with VGCC antibodies, and there was no association between Hu or VGCC antibodies and the extent of disease or survival.
Hu and VGCC antibodies are found in a proportion of SCLC patients, irrespective of neurologic symptoms, but their presence does not correlate with the prognosis of the SCLC.
此前已发现Hu抗体与小细胞肺癌（SCLC）患者的较长生存期相关。电压门控钙通道（VGCC）抗体在兰伯特-伊顿肌无力综合征中起致病作用，该综合征也与SCLC相关。这些抗体可能会减少患有神经疾病患者的肿瘤生长，但尚不清楚它们是否能为无神经症状的患者提供预后信息。
对200例接受化疗的SCLC患者（年龄39至79岁；平均62.3岁；男性129例，女性71例）进行Hu和VGCC抗体检测。采用基于体外转录-翻译的免疫沉淀技术以及免疫组织化学/斑点印迹法检测血清中的Hu抗体。通过放射免疫测定法检测VGCC（P/Q亚型）抗体。采用生存分析对数据进行分析。结果：通过基于体外转录-翻译的免疫沉淀法在200例患者中的51例（25.5%）检测到Hu抗体，通过免疫组织化学或斑点印迹法在200例患者中的37例（18.5%）检测到Hu抗体，而通过放射免疫测定法仅在200例患者中的10例（5%）检测到VGCC抗体。Hu抗体的存在与VGCC抗体不相关，且Hu或VGCC抗体与疾病范围或生存期之间无关联。
在一部分SCLC患者中发现了Hu和VGCC抗体，无论有无神经症状，但它们的存在与SCLC的预后不相关。
